US/UK/Canada

Share

Quotes

When I use the Össur POWER KNEE, I feel like I have my knee back.
Prosthetist John Arnold, who lost his limb in 2022 after a motorcycle accident
Pick a time period -
Tags ( Active)

Embla Medical hf: Conference call details for Q2 2026

Reykjavik, Iceland/Copenhagen, Denmark, 7 July 2026. Embla Medical (Nasdaq Copenhagen: EMBLA) will publish its Q2 2026 Report on July 21, 2026, at 7:00 CET. A conference call will be hosted on the same day at 9:00 CET / 7:00 GMT / 3:00am EST. The event will be hosted by Sveinn Solvason, President and CEO, and G. Arna Sveinsdottir, CFO. The call will include a review of the quarterly results and will be held in English. Slides used in the presentation will be made available on the company website at the following link: https://www.emblamedical.com/investors To participate in the

Embla Medical hf: Transactions in relation to Share Buyback Program

Announcement no. 34/2026 6 July 2026 Reykjavik, Iceland/Copenhagen, Denmark, 6 July 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 29 June to 3 July 2026 Embla Medical has acquired 57,000 shares under the Program at the average price of DKK 26.95. Following the transactions below, the Company holds 2,145,095 shares, corresponding to 0.50% of the Company’s

Embla Medical hf: Transactions in relation to Share Buyback Program

Announcement no. 33/2026 29 June 2026 Reykjavik, Iceland/Copenhagen, Denmark, 29 June 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 22 June to 26 June 2026 Embla Medical has acquired 113,000 shares under the Program at the average price of DKK 25.96. Following the transactions below, the Company holds 2,088,095 shares, corresponding to 0.49% of the Company’

Embla Medical hf: Transactions in relation to Share Buyback Program

Announcement no. 32/2026 22 June 2026 Reykjavik, Iceland/Copenhagen, Denmark, 22 June 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 15 June to 19 June 2026 Embla Medical has acquired 125,000 shares under the Program at the average price of DKK 26.89. Following the transactions below, the Company holds 1,975,095 shares, corresponding to 0.46% of the Company’

Embla Medical hf: Transactions in relation to Share Buyback Program

Announcement no. 31/2026 15 June 2026 Reykjavik, Iceland/Copenhagen, Denmark, 15 June 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 8 June to 12 June 2026 Embla Medical has acquired 107,000 shares under the Program at the average price of DKK 26.91. Following the transactions below, the Company holds 1,850,095 shares, corresponding to 0.43% of the Company’s

Embla Medical hf: Transactions in relation to Share Buyback Program

Announcement no. 30/2026 8 June 2026 Reykjavik, Iceland/Copenhagen, Denmark, 8 June 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 1 June to 4 June 2026 Embla Medical has acquired 58,784 shares under the Program at the average price of DKK 26.98. Following the transactions below, the Company holds 1,743,095 shares, corresponding to 0.41% of the Company’s

Embla Medical hf: Transactions in relation to Share Buyback Program

Announcement no. 29/2026 1 June 2026 Reykjavik, Iceland/Copenhagen, Denmark, 1 June 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 26 May to 29 May 2026 Embla Medical has acquired 83,854 shares under the Program at the average price of DKK 27.04. Following the transactions below, the Company holds 1,684,311 shares, corresponding to 0.40% of the Company’s

Embla Medical hf: Transactions in relation to Share Buyback Program

Announcement no. 28/2026 26 May 2026 Reykjavik, Iceland/Copenhagen, Denmark, 26 May 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 18 May to 22 May 2026 Embla Medical has acquired 108,000 shares under the Program at the average price of DKK 26.32. Following the transactions below, the Company holds 1,600,457 shares, corresponding to 0.38% of the Company’s

Embla Medical hf: Transactions in relation to Share Buyback Program

Announcement no. 27/2026 18 May 2026 Reykjavik, Iceland/Copenhagen, Denmark, 18 May 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 11 May to 13 May 2026 Embla Medical has acquired 101,000 shares under the Program at the average price of DKK 26.75. Following the transactions below, the Company holds 1,492,457 shares, corresponding to 0.35% of the Company’s

Embla Medical hf: Transactions in relation to Share Buyback Program

Announcement no. 26/2026 11 May 2026 Reykjavik, Iceland/Copenhagen, Denmark, 11 May 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 4 May to 8 May 2026 Embla Medical has acquired 94,015 shares under the Program at the average price of DKK 27,21. Following the transactions below, the Company holds 1,391,457 shares, corresponding to 0.33% of the Company’s total

Embla Medical hf: Transactions in relation to Share Buyback Program

Announcement no. 25/2026 4 May 2026 Reykjavik, Iceland/Copenhagen, Denmark, 4 May 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 27 April to 1 May 2026 Embla Medical has acquired 170,000 shares under the Program at the average price of DKK 26.95. Following the transactions below, the Company holds 1,297,442 shares, corresponding to 0.30% of the Company’s

Embla Medical hf: Interim Report Q1 2026

Announcement no. 24/2026 Interim Report Q1 2026 Sveinn Sölvason, President and CEO, comments: “Sales in the first quarter of 2026 reached USD 232 million, representing reported growth of 15% and organic growth of 4%. We delivered strong performance in Prosthetics & Neuro Orthotics, driven by continued momentum and solid volume growth across regions and categories. Bracing & Supports delivered moderate growth, while Patient Care experienced a softer quarter, largely driven by timing effects in Europe. We are seeing more favorable trends in the U.S. Patient Care business and

Embla Medical hf: Transactions in relation to Share Buyback Program

Announcement no. 23/2026 27 April 2026 Reykjavik, Iceland/Copenhagen, Denmark, 27 April 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 20 April to 24 April 2026 Embla Medical has acquired 148,000 shares under the Program at the average price of DKK 28.14. Following the transactions below, the Company holds 1,127,442 shares, corresponding to 0.26% of the

Embla Medical hf: Transactions in relation to Share Buyback Program

Announcement no. 22/2026 20 April 2026 Reykjavik, Iceland/Copenhagen, Denmark, 20 April 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 13 April to 17 April 2026 Embla Medical has acquired 121,000 shares under the Program at the average price of DKK 28.12. Following the transactions below, the Company holds 979,442 shares, corresponding to 0.23% of the

Embla Medical hf: Conference call details for Q1 2026

Reykjavik, Iceland/Copenhagen, Denmark, 20 April 2026. Embla Medical (Nasdaq Copenhagen: EMBLA) will publish its Q1 2026 Report on April 28, 2026, at 7:00 CET. A conference call will be hosted on the same day at 9:00 CET / 7:00 GMT / 3:00am EST. The event will be hosted by Sveinn Solvason, President and CEO, and G. Arna Sveinsdottir, CFO. The call will include a review of the quarterly results and will be held in English. Slides used in the presentation will be made available on the company website at the following link: https://www.emblamedical.com/investors To participate in the

Embla Medical hf: Transactions in relation to Share Buyback Program

Announcement no. 21/2026 13 April 2026 Reykjavik, Iceland/Copenhagen, Denmark, 13 April 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 7 April  to 10 April 2026 Embla Medical has acquired 60,000 shares under the Program at the average price of DKK 27.18. Following the transactions below, the Company holds 858,442 shares, corresponding to 0.20% of the Company’

Embla Medical hf: Transactions in relation to Share Buyback Program

Announcement no. 20/2026 7 April 2026 Reykjavik, Iceland/Copenhagen, Denmark, 7 April 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 30 March to 1 April 2026 Embla Medical has acquired 35,000 shares under the Program at the average price of DKK 26.35. Following the transactions below, the Company holds 798,442 shares, corresponding to 0.19% of the Company’s

Embla Medical hf: Transactions in relation to Share Buyback Program

Announcement no. 19/2026 30 March 2026 Reykjavik, Iceland/Copenhagen, Denmark, 30 March 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 23 March to 27 March 2026 Embla Medical has acquired 61,000 shares under the Program at the average price of DKK 26.44. Following the transactions below, the Company holds 763,442 shares, corresponding to 0.18% of the Company’

Embla Medical hf: Transactions in relation to Share Buyback Program

Announcement no. 18/2026 23 March 2026 Reykjavik, Iceland/Copenhagen, Denmark, 23 March 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 16 March to 20 March 2026 Embla Medical has acquired 50,000 shares under the Program at the average price of DKK 27.64. Following the transactions below, the Company holds 702,442 shares, corresponding to 0.16% of the Company’

Embla Medical hf: Transactions in relation to Share Buyback Program

Announcement no. 17/2026 16 March 2026 Reykjavik, Iceland/Copenhagen, Denmark, 16 March 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 9 March to 13 March 2026 Embla Medical has acquired 50,000 shares under the Program at the average price of DKK 29.34. Following the transactions below, the Company holds 652,442 shares, corresponding to 0.15% of the Company’

Embla Medical hf: Registration of capital reduction of 2,441,257 shares completed

Announcement no. 16/2026 13 March 2026 Reference is made to announcement no. 15/2026 published on 10 March 2026 (Embla Medical: Results of the Annual General Meeting 2026). Reykjavik, Iceland/Copenhagen, Denmark, March 13, 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced that the capital reduction of ISK 2,441,257 nominal value was registered with the Icelandic Register of Enterprises today. 2,441,257 of the Company’s own shares with a nominal value of ISK 1 each were cancelled. The share capital of Embla

Embla Medical hf: Results of the Annual General Meeting 2026

Announcement no. 15/2026 10 March 2026 Reykjavik, Iceland/Copenhagen, Denmark, 10 March, 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced the results from the 2026 Annual General Meeting. Results of the Annual General Meeting · The meeting approved to carry the Company’s net profit in 2025 over to the following year. · The meeting approved the Company’s Consolidated Financial Statements for the year 2025. · The meeting approved the Company’s Remuneration Policy. See attachment. · The meeting

Embla Medical hf: Transactions in relation to Share Buyback Program

Announcement no. 14/2026 9 March 2026 Reykjavik, Iceland/Copenhagen, Denmark, 9 March 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 2 March to 6 March 2026 Embla Medical has acquired 48,000 shares under the Program at the average price of DKK 30.02. Following the transactions below, the Company holds 3,043,699 shares, corresponding to 0.71% of the Company’s

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media